The present invention discloses therapeutic or preventive agents for diabetes having a thiazolidine belonging to PPAR-γ agonist as one of effective ingredient and therapeutic or preventive agents for diabetes which can decrease the side effects concerning PPAR-γ agonist. The therapeutic or preventive agents for diabetes comprise a specific IP agonist (such as beraprost sodium (BPS), etc.) and thiazolidine derivatives (such as pioglitazone or its pharmaceutically acceptable salts, etc.). The therapeutic or preventive agents of the present application shows a fully effective hypoglycemic effect because it does not go with a characteristic side effects (such as gain weight). Accordingly, it is useful as the therapeutic or preventive agents for diabetes with security and high efficacy.掲示將屬於PPAR-γ激動劑之噻唑啶衍生物作為1有效成分之糖尿病之治療或預防藥、PPAR-γ激動劑之副作用被減輕之糖尿病之治療藥或預防藥。糖尿病之治療或預防藥為含有如貝前列素(beraprost)鈉(BPS)等特定之IP激動劑,與如吡咯列酮(pioglitazone)或其藥理學容許鹽等噻唑啶衍生物。本發明之治療藥或預防藥因不伴隨PPAR-γ激動劑之特徵性副作用(例如體重增加)而呈示充分有效之降血糖作用,故作為安全性、有效性高之糖尿病之治療藥或預防藥有用。
